{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":" \ud83d\udd25 The 25% Effect: Retatrutide Redefines Weight Loss","description":"In TRIUMPH-1, once-weekly retatrutide produced mean weight loss of up to 25% at 80 weeks\u2014but the story extends beyond the scale. \u2696\ufe0f \ud83e\uddb5 Less knee osteoarthritis pain \ud83d\ude34 Fewer obstructive sleep apnea events \u2764\ufe0f Improved cardiometabolic measures \ud83e\ude78 89\u201393% with prediabetes reverted to normoglycemia A triple GIP\/GLP-1\/glucagon receptor agonist may reshape how we think about obesity: not simply kilograms lost, but disease burden reduced. \ud83d\udca1 \u26a0\ufe0f Gastrointestinal adverse effects remain important. ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/43154243\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/207053058"}